TY - JOUR
KW - Young Adult
KW - Rifampin
KW - polymerase chain reaction
KW - Mycobacterium leprae
KW - Mutation
KW - Mice, Inbred BALB C
KW - Mice
KW - Male
KW - Leprostatic Agents
KW - Humans
KW - Gene Expression Regulation, Bacterial
KW - DNA, Bacterial
KW - Biological Assay
KW - Bacterial Proteins
KW - Animals
KW - Amino Acid Sequence
KW - Adult
AU - Lavania M
AU - Hena A
AU - Reja H
AU - Nigam A
AU - Biswas NK
AU - Singh I
AU - Turankar R
AU - Gupta U
AU - Kumar S
AU - Rewaria L
AU - Patra P
AU - Sengupta U
AU - Bhattacharya B
AB - <p><strong>BACKGROUND: </strong>Rifampicin is the major drug in the treatment of leprosy. The rifampicin resistance of Mycobacterium leprae results from a mutation in the rpoB gene, encoding the β subunit of RNA polymerase. As M. leprae is a non-cultivable organism observation of its growth using mouse food-pad (MFP) is the only Gold Standard assay used for confirmation of "in-vivo" drug resistance.</p>

<p><strong>OBJECTIVE: </strong>Any mutation at molecular level has to be verified by MFP assay for final confirmation of drug resistance in leprosy.</p>

<p><strong>MATERIAL AND METHODS: </strong>In the present study, M. leprae strains showing a mutation only at codon 442 Gln-His and along with mutation either at codon 424 Val-Gly or at 438 Gln-Val within the Rifampicin Resistance Determining Region (RRDR) confirmed by DNA sequencing and by high resolution melting (HRM) analysis were subjected for its growth in MFP.</p>

<p><strong>RESULT AND CONCLUSION: </strong>The M. leprae strain having the new mutation at codon 442 Gln-His was found to be sensitive to all the three drugs and strains having additional mutations at 424 Val-Gly and 438 Gln-Val were conferring resistance with Multi drug therapy (MDT) in MFP. These results indicate that MFP is the gold standard method for confirming the mutations detected by molecular techniques.</p>

BT - Leprosy review
C1 - <p>http://www.ncbi.nlm.nih.gov/pubmed/27255062?dopt=Abstract</p>

IS - 1
J2 - Lepr Rev
LA - eng
N2 - <p><strong>BACKGROUND: </strong>Rifampicin is the major drug in the treatment of leprosy. The rifampicin resistance of Mycobacterium leprae results from a mutation in the rpoB gene, encoding the β subunit of RNA polymerase. As M. leprae is a non-cultivable organism observation of its growth using mouse food-pad (MFP) is the only Gold Standard assay used for confirmation of "in-vivo" drug resistance.</p>

<p><strong>OBJECTIVE: </strong>Any mutation at molecular level has to be verified by MFP assay for final confirmation of drug resistance in leprosy.</p>

<p><strong>MATERIAL AND METHODS: </strong>In the present study, M. leprae strains showing a mutation only at codon 442 Gln-His and along with mutation either at codon 424 Val-Gly or at 438 Gln-Val within the Rifampicin Resistance Determining Region (RRDR) confirmed by DNA sequencing and by high resolution melting (HRM) analysis were subjected for its growth in MFP.</p>

<p><strong>RESULT AND CONCLUSION: </strong>The M. leprae strain having the new mutation at codon 442 Gln-His was found to be sensitive to all the three drugs and strains having additional mutations at 424 Val-Gly and 438 Gln-Val were conferring resistance with Multi drug therapy (MDT) in MFP. These results indicate that MFP is the gold standard method for confirming the mutations detected by molecular techniques.</p>

PY - 2016
SP - 93
EP - 100
T2 - Leprosy review
TI - Mutation at codon 442 in the rpoB gene of Mycobacterium leprae does not confer resistance to rifampicin.
UR - https://leprosyreview.org/article/87/1/09-3100
VL - 87
SN - 0305-7518
ER -